Australia's Immutep hits 15-month high on positive IMP761 trial update
I'm PortAI, I can summarize articles.
** Shares of Australia's Immutep rise as much as 3.8% to A$0.415, their highest since September 13, 2024** Biotech firm announces positive update from IMP761 first-in-human Phase I study, a LAG-3 agonist antibody for autoimmune diseases** Co reports dose-dependent immunosuppressive effects of IMP761 against a strong foreign antigen, maintaining a favorable safety profile** Further updates for trial expected in H1 CY2026 - Immutep** IMM down 12.3% YTD
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments